Mark Koba is a senior editor at CNBC.com. Topics for his feature story writing include the business of politics, health care, employment and the economy.
Before working at CNBC.com, he spent 11 years at Bloomberg LP, where among various duties, he was program producer for the award-winning "Bloomberg Small Business" television show.
Koba's background includes a decade of news writing and show producing at CNN, E! Entertainment Television, ABC's "World News Now," "Good Morning America" and CBS' "This Morning."
Follow Mark Koba on Twitter @MarkKobaCNBC.
In our Innovations segment--we have the first hearing aid to use nanotechnology. It's been so successful--it's pushed the revenue growth for the company that makes the aid--past 35% in a year. The company is Starkey Labs and the firm's president-Jerry Ruzicka talked about the device with Sue Herera on "Power Lunch."
Companies and advertisers usually have no shame in imitating an ad that really works--but rarely do you see a company copy itself. But that's exactly what Volkswagen is doing with its new Passat ads--after the success it had with the same idea for Jetta. Will it work?
Good morning. Our quote of the day comes from Thomas Jefferson: "You have to have your heart in the business and the business in your heart." The economic calendar will get attention today as the revised Q3 Productivity--Factory Orders and ISM Services reports are due to be released.
We've been telling you about Pfizer's troubles today--that it stopped development of what was supposed to be its blockbuster drug--torcetrapib. Unfortunate deaths during clinical testing forced Pfizer to cancel the drug. It was supposed to be the successor to Lipitor. And as a result of the failure--a question is being raised--will the failed tests change the way pharmaceutical drugs are approved?
Hedge funds are heading into a rough few weeks. Many funds are looking at some pretty average returns this year--and if that's not bad enough--the industry faces U.S. Congressional hearings starting tomorrow on regulations and insider trading. William Galvin is Secretary of the Commonwealth of Massachusetts...
Signs of a slowing economy plus some risk of recession has many economists wondering if the Fed will be forces to cut rates soon than later. In our exclusive interview on cnbc.com earlier today-Chicago Fed President Michael Moskow said he thought the focus was on the U.S. housing sector--and to some extent autos as well--and if those slowing sectors will spill into other areas.
The super rich are taking ever bigger slices of the U.S. economic pie and leaving only crumbs for the rest of America. That is the premise of a Paul Krugman article in the new issue of Rolling Stone. Krugman is a columnist for the New York Times and writes for RS. Krugman appeared on "Power Lunch"...
This past Saturday night--Pfizer announced it's stopping production of its new anti-cholesterol drug torcetrapib. Unfortunately--clinical test results showed more deaths than were expected from taking the experimental drug. Catherine Arnold is a pharmaceutical analyst from Credit Suisse..
Hugo Chavez easily won re-election as president of Venezuela on Sunday. Chavez called his re-election--a defeat for U.S. President George Bush. Chavez said he will continue to use Venezuela's oil to expand social welfare programs--and continue to challenge the U.S. in Latin America. It's no secret the two men don't like each other.